FluoGuide is trading at SEK 31.30, down 5.15%, amid broader biotech-sector pressure. - Biotech ETF XBI fell 2.04%, consistent with sector pressure. - No new FluoGuide-specific announcement was identified for October 9. The latest updates found—its U.S. Phase 2 trial and Leica collaboration—were announced earlier in October. - Recent macro risk-off conditions may add context, but no direct link to FluoGuide’s decline is established.